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Abstract
Background: Depression is a highly prevalent and costly disorder. Effective treatments are available but are not
always delivered to the right person at the right time, with both under- and over-treatment a problem. Up to half
the patients presenting to general practice report symptoms of depression, but general practitioners have no
systematic way of efficiently identifying level of need and allocating treatment accordingly. Therefore, our team
developed a new clinical prediction tool (CPT) to assist with this task. The CPT predicts depressive symptom severity
in three months’ time and based on these scores classifies individuals into three groups (minimal/mild, moderate,
severe), then provides a matched treatment recommendation. This study aims to test whether using the CPT
reduces depressive symptoms at three months compared with usual care.
Methods: The Target-D study is an individually randomized controlled trial. Participants will be 1320 general
practice patients with depressive symptoms who will be approached in the practice waiting room by a research
assistant and invited to complete eligibility screening on an iPad. Eligible patients will provide informed consent
and complete the CPT on a purpose-built website. A computer-generated allocation sequence stratified by practice
and depressive symptom severity group, will randomly assign participants to intervention (treatment recommendation
matched to predicted depressive symptom severity group) or comparison (usual care plus Target-D attention control)
arms. Follow-up assessments will be completed online at three and 12 months. The primary outcome is depressive
symptom severity at three months. Secondary outcomes include anxiety, mental health self-efficacy, quality of life, and
cost-effectiveness. Intention-to-treat analyses will test for differences in outcome means between study arms overall
and by depressive symptom severity group.
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Discussion: To our knowledge, this is the first depressive symptom stratification tool designed for primary care which
takes a prognosis-based approach to provide a tailored treatment recommendation. If shown to be effective, this tool
could be used to assist general practitioners to implement stepped mental-healthcare models and contribute to a
more efficient and effective mental health system.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR 12616000537459). Retrospectively registered
on 27 April 2016. See Additional file 1 for trial registration data.
Keywords: Depression, Clinical prediction tool, Prognosis, Stepped care, General practice, Randomized controlled trial
Background
Background and rationale
Depression affects at least 350 million people worldwide
[1] and is a leading cause of non-fatal burden of disease
[2]. It is costly to individuals in terms of relationships
and functioning and to society in terms of direct medical
costs and costs due to loss of individual productivity [3].
Despite significant investments in mental health globally,
there is no evidence of a reduction in the burden of dis-
ease associated with depression [4]. One of the biggest
challenges facing mental healthcare systems is the need
to develop efficient methods of allocating clinically ef-
fective treatment in a cost-effective way to the people
that need them most [5].
The majority of depression cases are identified, treated,
and followed up in primary care [6]. However, general prac-
titioners (GPs) have been criticized for both under- and
over-diagnosing, and treating, depression [7–10]. For ex-
ample, only 16% of Australians with case level depression
or anxiety receive an adequate “dose” of an evidence-based
intervention consistent with treatment guidelines [9]. On
the other hand, antidepressant prescriptions far outnumber
patients for whom such medication is indicated [11].
Multi-country studies report that 24–55% of patients
in primary care waiting rooms meet screening criteria
for being “probably depressed” [12]. However, among this
population of “probably depressed,” a range of illness trajec-
tories exist which contribute to the difficulty experienced
by practitioners in making a diagnosis and treatment rec-
ommendation [13–18]. It may be that the heterogeneity of
clinical presentation which characterizes depression in the
primary care setting is leading to the simultaneous prob-
lems of both over- and under-diagnosis and treatment.
Currently, there is a mismatch in primary care be-
tween patient need and the depression care received,
possibly as a result of poor treatment allocation. For ex-
ample, delivery of intensive interventions to people with
minimal or mild symptoms is unnecessarily costly and
risks medicalizing normal fluctuations in mood [19].
Conversely, without a targeted intensive intervention,
people likely to experience severe and chronic symptoms
are likely to experience significant disability, which could
have been avoided [20, 21].
Stepped care models, in which patients are, in the first
instance, provided with the least time- and resource-
intensive intervention that will be effective [22], have
been promoted as a potential solution to the problem of
poor treatment allocation. Although limited empirical
evidence exists as to their effectiveness [23], these models
make intuitive sense and feature in both clinical guidelines
and policy directives in Australia [24] and the UK [22].
Currently, a key obstacle to the implementation of stepped
care models is the lack of effective treatment allocation
tools to guide GPs in matching the intensity of treatment
to a patient’s needs. In particular, current recommenda-
tions focus on matching treatment to the patient’s current
symptom severity, rather than patient’s likely course of ill-
ness in the future. This is out of step with the manage-
ment of other conditions (e.g. cardiovascular disease or
cancer), which routinely take prognostic factors into ac-
count when deciding upon treatment recommendations.
Further, it contrasts with calls for research, policy, and
practice to make prognosis-based intervention a priority
[25]. To date, there has been no quick and systematic way
for GPs to identify depression outcomes that a particular
person is likely to experience in the future and recom-
mend treatment accordingly.
One option for systematizing treatment recommenda-
tions is to use a clinical prediction tool (CPT). CPTs are
based on a prognostic model that uses clinical and non-
clinical information to estimate an individual’s risk of a
specific outcome [26]. The prognostic model is applied
in clinical practice using the CPT which stratifies patients
into different treatments according to their estimated risk
[27]. While CPTs are common in many fields of medicine,
they are not readily available for use in mental-healthcare
settings. [28]
To address this gap, we wanted to develop a simple,
easy-to-use CPT to assist primary care clinicians to triage
patients presenting with depressive symptoms and allocate
to appropriate treatment. First, we investigated whether
an existing prognostic model for depression could be used
to build the CPT. We identified several prognostic models
that have been developed to predict current [29, 30] or
future major depression [31–34] or treatment response
[35–37]. However, none of these prognostic models were
Gunn et al. Trials  (2017) 18:342 Page 2 of 14
found to be suitable for incorporating into a CPT which
could be easily administered in routine care [38].
Therefore, we developed a novel prognostic model
using data from the diamond cohort study [39] to pre-
dict depressive symptom severity at three months [38].
It comprises 17 items assessing depressive symptom se-
verity at baseline as measured by the Patient Health
Questionnaire-9 (PHQ-9) [40]: sex; current anxiety; his-
tory of depression; presence of chronic illness affecting
daily functioning; self-rated health; living alone; and per-
ceived ability to manage on available income. Based on
an individual’s score, he or she is stratified into one of
three groups based on predicted depressive symptom
scores at three months; namely, minimal/mild (those
predicted to have a PHQ score of ≤ 10 at three months),
moderate (PHQ > 10 and < 13), and severe (≥13). Cutoffs
for the three groups were established during the devel-
opment of the diamond CPT and are explained in full
elsewhere [38]. In the intervention being tested in the
current study, individuals are then:
(1)Presented with feedback reflecting their responses to
the CPT;
(2)Provided an opportunity to set priorities and reflect
on motivation to change; and
(3)Presented with an evidence-based treatment
recommendation matched to group classification.
The presentation of feedback and treatment recommen-
dation was informed by the principles of motivational
interviewing [41] and an iterative development process
employing user-centered design principles to ensure the
information is presented in a way that is meaningful and
engaging for participants [42].
Objectives
The Target-D randomized controlled trial (RCT) aims to
test whether using the diamond CPT to tailor treatment
recommendations to an individual’s predicted depressive
symptom severity is a clinically effective and economic-
ally efficient way of reducing depressive symptoms, rela-
tive to usual care. This paper presents the study protocol
for the Target-D RCT, adhering to the SPIRIT guidelines
for intervention trial designs ([43]; see Additional file 2
for SPIRIT checklist).
The primary objective of the Target-D trial is to deter-
mine if using the diamond CPT to triage individuals with
depressive symptoms into symptom severity-appropriate
treatment reduces depressive symptoms at three months
compared with usual care.
Secondary objectives are to: (1) test whether individuals
in the intervention and comparison arms differ in depres-
sive symptom severity at 12 months, quality of life, anxiety
symptoms, self-efficacy, and health service use at three
and 12 months; (2) determine whether the outcomes differ
between the two study arms within each of the three de-
pressive symptom severity groups; and (3) evaluate the
cost-effectiveness of the new model of care compared to
usual care.
Trial design
Target-D is a stratified individually RCT with two paral-
lel arms, modelled on the trial undertaken by Hill et al.
who tested the stratified management of low back pain
[44]. Participants will be randomized to the intervention
or usual care arm with 1:1 allocation, stratified by gen-
eral practice and predicted depressive symptom severity
group. Participants in the intervention arm will be cate-
gorized into one of three treatment groups according to
their diamond CPT results; participants in the usual care
arm will complete the diamond CPT but will not receive
feedback, an opportunity for reflection, or a treatment
recommendation specific to their predicted depressive
symptom severity. An intention-to-treat (ITT) approach
will be used in the analysis (explained further below).
Methods
Participants, interventions, and outcomes
Study setting
The study will be conducted in at least ten general prac-
tices in Victoria, Australia (see Additional file 3 for the
location of study sites).
Eligibility criteria
General practices will be eligible if they: see more than
50 adults aged 18–65 years per day; agree to waiting
room screening; have a private space available to be used
for the Target-D intervention; and have the majority of
their GPs willing collaborate with the Target-D team.
Patients attending participating general practices will
be assessed for eligibility using a self-report survey de-
livered via an iPad. Patients will be eligible if they score
2 or more on the two-item version of the Patient Health
Questionnaire (PHQ-2) [45] (indicating depressive symp-
toms but not necessarily a diagnosis of major depressive
disorder), are aged 18–65 years, have access to the Inter-
net for the duration of follow-up, have sufficient written
English to follow an Internet-based cognitive behavioral
therapy (iCBT) program, have not changed depression
medication in the past month (if they take such medica-
tion), and agree to randomization to either the usual care
or intervention arm. They will be ineligible if they are cur-
rently taking antipsychotic medication, are regularly seeing
or planning to see a psychologist in the next three months,
or are currently using an iCBT program. Eligible patients
will be asked to provide informed consent online (see
Additional file 4) and complete baseline measures prior to
completing the diamond CPT.
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Intervention
Participants will complete the diamond CPT online on a
purpose-built study website (henceforth referred to as
the Target-D website). They will then be contacted by
phone by a trained research assistant (RA) to provide
encouragement and support and answer questions as ne-
cessary. This phone call will occur within one week of
diamond CPT completion.
Intervention arm
As described above, the intervention being tested comprises
feedback on CPT responses, an opportunity to set prior-
ities, and a treatment recommendation (based on predicted
depressive symptom severity). Immediately after complet-
ing the diamond CPT, participants in the intervention arm
will see these components displayed on sequential pages of
the Target-D website.
The follow-up phone call from an RA will involve a
discussion about the treatment recommendation they re-
ceived, using the results of the diamond CPT to tailor
the discussion to the individual’s classification. To encour-
age treatment engagement, this discussion will use motiv-
ational interviewing, an approach to conversations that
promotes collaboration and aims to strengthen the person’s
motivation and commitment to making a change [41].
The recommended treatment for each of the three
groups were selected based on a stepped care approach
[22], with treatment intensity lowest in the minimal/mild
group and highest in the severe group. To select the spe-
cific treatments offered to each level of intensity, we ex-
amined existing primary care data from the diamond
cohort study to describe the characteristics, treatment,
and service use of individuals stratified to each group.
We also reviewed systematic reviews of the evidence
relevant to each group and presented these findings to
our investigator team to inform treatments offered. An-
other comprehensive description of the interventions
delivered, using the TIDier checklist, will be included
in the primary outcome paper as per Hoffmann et al.
[46] and CONSORT guidelines.
Minimal/mild depressive symptoms at three months
Participants who are likely to have minimal or mild de-
pressive symptoms at three months will be offered self-
help and automated follow-up using the myCompass
iCBT program which has been shown in randomized trials
to be effective in improving outcomes for patients with
mild depression [47, 48]. myCompass is an interactive,
self-help Internet resource consisting of information, ac-
counts of others’ experiences, treatment modules with
home tasks, and mood tracking functions. myCompass
uses an internal algorithm to recommend components tai-
lored to participant symptoms and needs. Participants can
choose to follow the recommendation or not and may
undertake components of the program in any order.
Participants in the minimal/mild group will receive
two automated emails from the research team to encourage
uptake and adherence to the treatment recommendation.
These emails will be sent immediately after the participant
receives the recommendation to use myCompass and one
week later and are in addition to any correspondence the
participant receives from the myCompass program.1 Emails
will provide participants with the link to myCompass, en-
couragement to get started, and reminders of some of the
benefits of the program. This will mimic what would be
feasible in the routine clinical setting.
Moderate depressive symptoms at three months The
moderate group will be offered clinician-guided iCBT via
the Worry and Sadness course in the This Way Up pro-
gram, which has randomized trial evidence of effective-
ness in reducing moderate symptoms of depression [49].
This Way Up comprises six structured online lessons
using CBT principles and includes lessons in the form of
an illustrated story about someone with depression,
printable summaries, and homework assignments, and
symptom monitoring at the beginning of each session
[49]. Lessons are completed in a linear order and each
becomes available five days after the previous lesson is
completed.
Target-D will follow standard This Way Up protocol,
with participants provided with weekly individualized
support via phone/email, until they have completed
Lesson Two [49]. Support will include positive encour-
agement to commence or continue treatment, reiterate
the importance of homework completion, and respond
to general questions by referring back to program mate-
rials. This role will be filled by RAs, in line with evidence
supporting the effectiveness of non-clinician provided
support to This Way Up users [50]. In keeping with
published protocol [49], after the completion of Lesson
Two phone contact will be made in response to patient
request or a deterioration in condition (defined as an
increase of ≥ 5 on the PHQ-9 [51]).
Severe depressive symptoms at three months The se-
vere group will be offered collaborative care, an en-
hanced form of patient care shown to be effective for
treatment of moderate to severe depression in primary
care [21, 52–54]. Collaborative care is defined as includ-
ing four key ingredients: a multi-professional approach
to patient care; a structured management plan; scheduled
follow-ups; and coordinated communication between
health professionals involved in management [21, 55].
Target-D participants involved in collaborative care will
receive eight appointments with a trained case manager
(CM). The CM role will be filled by a non-mental-health
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specialist such as a registered nurse. This decision was
made as it is in keeping with the role filled by practice
nurses in managing other chronic conditions such as dia-
betes and thus should enhance scalability of the Target-D
model of care should it be effective.
The Target-D approach to collaborative care is under-
pinned by the principles of motivational interviewing, to
enhance patient engagement and action. The Target-D
CM will receive training in the intervention approach by
a qualified psychologist and will receive regular supervi-
sion and support from the psychologist and project
manager (SF) throughout the trial.
Patients in this group will be reminded of upcoming
appointments with the Target-D CM via SMS. After each
appointment, patients will receive an email from their
CM summarizing their discussion and outlining the ac-
tions the patient intends to take to manage his/her men-
tal health. With the patient’s consent, the CM will also
send a copy of this email to the treating GP and other
professionals involved in the patient’s mental healthcare.
Comparison arm
Participants randomized to the comparison arm will ac-
cess health services as usual. The choice of “usual care”
as a comparator was made as the study aims to deter-
mine the extent to which the intervention improves (or
worsens) patient outcomes relative to standard practice
[56]. Participants in this arm will also receive some non-
therapeutic attention from Target-D to control for any
effect of contact with the study team following completion
of the diamond CPT; thus, this study arm is referred to as
“Usual care plus Target-D” or UC+. UC+ participants will
be blinded to their depressive symptom severity group
allocation and will not receive a tailored treatment rec-
ommendation. Instead, they will see a screen on the
Target-D website advising them that they will be asked
to provide feedback on: (1) their opinions on research
in primary care; and (2) how they normally manage
their emotional health and wellbeing. Similar to the
procedure for intervention participants, those in the
usual care arm will be contacted by phone by an RA
within one week of diamond CPT completion. The RA
will reiterate the importance of the participant’s in-
volvement in the study, ask a series of structured ques-
tions about the participant’s views on research and the
involvement of their general practice in research, and
advise the participant that he or she will be contacted
via email in 12 weeks.
Modifications
The nature of the study interventions is such that no
substantive modifications are anticipated. Patients in the
minimal/mild and moderate groups may discontinue
using the online program at any time and treatment for
those in the severe group may be discontinued at patient
request.
If any participant indicates high levels of suicidal idea-
tion during contact with a member of the study team (as
indicated by a response of “nearly every day” to question
9 on the PHQ-9: “thoughts that you would be better off
dead or of hurting yourself in some way”), regardless of
study arm allocation, a standardized suicidal ideation
assessment used previously by the study team will be
administered and the patient’s GP alerted. This will be
reported as an adverse event but is unlikely to result in
treatment discontinuation or modification. The assess-
ment will determine if the adverse event was related
directly to the intervention or other circumstances not
intervention related.
Concomitant care
In both the usual care and intervention arms, partici-
pants will be permitted to continue any treatment they
were engaged with at entry to the trial. Concomitant
care will be assessed via self-report questionnaire and
routinely collected Government data (see below).
Treatment adherence
In the intervention arm, adherence to treatment in the
minimal/mild and moderate depressive severity groups
will be assessed using website analytics within myCom-
pass and This Way Up (i.e. tracking individual log-ins,
access of components, completion of modules and les-
sons). In the severe group, adherence to the treatment
plan will be assessed by the Target-D CM as part of the
planned follow-up schedule.
In the control arm, in order to compare “usual care”
before and during participation in the trial, information
about health service use will be collected at each study
assessment (see below).
Outcomes
Outcome measures will be collected at baseline and
three and 12 months post randomization. These time
points were selected to balance the benefits of multiple
assessments against the risk of unduly burdening partici-
pants. They allow us to examine both the immediate
and longer-term effect of the intervention and, because
they are commonly used in trials of mental-health inter-
ventions, will permit comparisons to be drawn with other
relevant studies.
Primary outcome
The primary outcome is the difference between the two
treatment arms in mean depressive symptom severity at
three months, controlling for baseline depressive symp-
tom severity. Depressive symptom severity was selected
as the outcome measure rather than a clinical diagnosis
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of major depressive disorder as it is more relevant to the
design and delivery of stepped mental healthcare.
Secondary outcomes
Secondary outcomes include difference between study arms
in mean depressive symptom severity at 12 months and
mean mental-health self-efficacy and anxiety at three and
12 months. The cost-effectiveness of the intervention
over the study period will comprise an additional second-
ary outcome.
Sample size
Sample size calculation was based upon our trial experi-
ence, a systematic review of depression trials [55] and
current data from the diamond study [39]. The primary
objective is to test for a standardized effect size of 0.2SD
in mean depressive symptoms at three months between
the intervention and comparison arms. However, we
based our calculations on our planned subgroup analyses
because the sample size required would need to be lar-
ger to test for difference between study arms within each
of the three depressive symptom severity groups than
combined. Therefore, we based sample size on detecting
a standardized mean difference of 0.2 between arms for
the minimal/mild group (given the potential floor effect
we anticipate a smaller intervention effect). We hypothe-
sized a standardized effect size of 0.5 in the moderate
and severe depressive symptom severity groups as they
have room for greater improvement and will receive
more intensive treatments.
Based on the CPT development work, we anticipated
that 70% of participants will be classified as being likely
to have minimal/mild depressive symptoms, 15% as
moderate, and 15% as severe depressive symptoms at
three months. We used these estimates to extrapolate
the total sample size needed to ensure that we had suffi-
cient power for the sub-group analyses. Based on these as-
sumptions, we required 158 (78 in each arm) participants
in each of the moderate and severe groups to detect a
standardized effect size of 0.5 and 740 (370 in each arm)
in the mild/minimal group to detect a smaller standard-
ized effect size of 0.2, with 80% power and 5% significance
level for a two-sided test.
This leads to an anticipated sample size of 1056 partic-
ipants (528 in each arm), which is also sufficient for the
primary objective to detect a standardized effect size of
0.2 in the mean PHQ-9 between study arms, with 90%
power and 5% significance level. A standardized effect
size of 0.2 is equivalent to a mean change of 1.35 points
in the mean depressive symptoms assuming a standard
deviation on 6.75 (based on diamond data). This effect
size is in keeping with those found in systematic reviews
of interventions to decrease depressive symptom severity
in primary care [57].
We inflated the required sample size to 1320 to allow
for 20% attrition at 12 months. Based upon documented
response rates and depressive symptom prevalence gath-
ered from our experience of recruiting participants with
depressive symptoms in the primary care setting [39],
achieving this sample size at baseline requires that we
invite 22,000 adults to complete the screening tool (Fig. 1).
Recruitment
Study sites
We will follow principles of good recruitment by en-
gaging with all stakeholders, branding the Target-D trial,
and using a well-developed engagement strategy [58].
We will recruit general practices via our Victorian Pri-
mary Care Practice-Based Research Network (VicReN),
which has around 200 GP members located in Victoria,
Australia. Practices will be contacted by phone and/or
email to introduce the study and establish interest. One
of the Target-D researchers will then visit interested
practices to determine eligibility, provide detailed infor-
mation about the study, and gain consent to participate.
This process will continue until sufficient practices are
recruited to obtain the required sample size.
To enhance GP and practice staff engagement in the
trial and the activities necessary to make it function, we
will be guided by the principles of Normalization Process
Theory (NPT) [59]; namely, coherence (meaning of the
trial to GPs and staff ), cognitive participation (commit-
ment and engagement), collective action (the work GPs
and staff do to make the trial function), and reflexive
monitoring (GP and staff appraisal of the trial). In each
participating practice, GPs and staff will be given a train-
ing session clarifying the goals and activities of the trial, in
order to instill a sense that the trial is a good idea and
worth committing to. In addition, we will clearly outline
the trial procedures and how they are likely to affect the
work of the practice, with emphasis on how the trial fits
with the overall goals of the general practice.
Minimizing contamination
Randomizing individuals that were recruited from the same
general practice, where the clinician is not blinded to the
participant’s study arm or the intervention is implemented
at the practice level, may have a greater risk of contamin-
ation between intervention and comparison arms than ran-
domizing a group of individuals that do not belong to the
same practice [60]. However, the risk of contamination in
this trial is expected to be minimal because of several fac-
tors. First, recruitment of participants will be conducted in
the waiting room by an RA who is not involved in deliver-
ing the study intervention and has no access to the allo-
cation schedule. While patients in the waiting room or
from the same family or friendship groups may share
information, it is unlikely that this will impact the
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intervention effect as the intervention can only be
accessed by permission of the study team. Second,
GPs will only be informed of participants allocated to
collaborative care treatment. Even if other patients in-
form their GP that they are participating in Target-D,
GPs will not be informed of their treatment allocation
nor be able to access study interventions for UC+ pa-
tients. Third, the intervention for minimal/mild groups
will be via Internet-based programs delivered outside the
practice, reducing the potential for practice-based contam-
ination. We will assess the number of UC+ participants
registering for these programs to measure the degree of
potential contamination. Fourth, the risk that GPs may
implement some of the intervention to patients predicted
to have severe symptoms and allocated to the UC+
group is small. We anticipate that fewer than ten such
participants will be recruited per practice and this small
number of patients will be seen by different GPs. We
have successfully used a similar approach in a previous
RCT in general practice; data from this trial showed
very low levels of interaction between comparison par-
ticipants and the GP during the study time-frame [61].
Primary care patients
Potential participants will be alerted to the study via
posters and information pamphlets displayed in practice
waiting rooms; an awareness raising strategy used by the
research team previously. All study materials and proce-
dures were developed and tested with focus groups and
individual feedback to ensure they are engaging and
user-friendly. Upon completion of the screening survey,
eligible participants will enter their name, telephone
number, and email address into an online form. They
will then be presented with an electronic copy of the
plain language statement and provide online consent to
participate.
To achieve our required sample size, trained RAs will
approach an average of 50 adults per practice per day,
taking approximately 440 working days to approach our
required 22,000 adults. These numbers are typical of
RCTs in primary care and we have achieved similar
numbers in previous successful studies [39, 62, 63].
While this number may seem ambitious, several factors
contribute to it being achievable. First, we have designed
the trial so that participants are recruited by RAs rather
than expecting already time-pressured GPs and practice
staff to take responsibility for recruitment. Second, the
22,000 patients RAs will approach include all adult pa-
tients in the waiting room; RAs or practice staff are not
required to identify only those patients who are present-
ing to the GP for mental health reasons. Finally, we have
tried this approach out in a clinic and shown that on
Fig. 1 Expected progression of participants through the study
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weekdays alone an RA can approach at least 50 patients
per day and invite 1100 patients per month to the study.
Our pilot work has shown that an RA spends only 1 or
2 min with each patient and can comfortably approach
150 patients in a working day. Based on this experience
and after accounting for weekend recruitment in some
practices, we anticipate participant recruitment to take
place over approximately 18 months. Recruitment of
participants will continue until the numbers within each
depressive symptom severity group have been met.
Assignment of interventions
Allocation
Consent and baseline measures will be collected prior to
randomization to minimize reporting and selection bias.
When the individual has completed the diamond CPT,
he or she will be randomly assigned in a 1:1 ratio to the
intervention or comparison arm. Randomization will be
stratified by general practice and depressive symptom se-
verity group. The allocation sequence will be computer-
generated sequentially within stratum using a biased-coin
algorithm [64] embedded within the Target-D website
which is housed on the secure National eResearch Collab-
oration Tools and Resources (Nectar) cloud which pro-
vides computing infrastructure to Australian researchers.
Using restricted randomization within the stratum ensures
that number of individuals is balanced between study arms
within stratum and the stratification factors will be
balanced in each study arm. The randomization will
be triggered automatically within the Target-D website,
after a participant has completed baseline measurements
and the diamond CPT, thus ensuring allocation
concealment.
Blinding
Due to the nature of the intervention, participants can-
not be blinded to their treatment allocation. However,
GPs will not be notified of their patients’ allocation to ei-
ther intervention or comparison arm. No emergency
unblinding of GPs is anticipated, including in the case of
the research team alerting the GP to patient suicidality.
As outcome assessment is conducted online, no blinding
of outcome assessors is required. All study analyses will
be conducted by a statistician blind to participants’ al-
location; study arm allocation will be coded as A or B,
with the code for the study arm revealed only after data
are analyzed.
Data collection
Participant data will be collected from intervention and
comparison arms using validated questionnaires on the
Target-D website at screening, baseline and three and
12 months (Fig. 2). diamond CPT data will also be col-
lected on the Target-D website. Participants will receive
an automated email from the website at 80 and 358 days
after diamond CPT completion with a unique link to
the three-month and 12-month survey, respectively.
Participants will be informed that if they decide to
withdraw from the study, the data already provided will
be retained and used in the analyses unless they request
otherwise.
Measures
Demographic characteristics, including age, gender, highest
level of education, and employment status, will be assessed
at baseline.
Primary outcome
Depressive symptom severity will be assessed at each
timepoint using the PHQ-9. The PHQ-9 assesses the
nine DSM symptoms of depression over the last two
weeks using a 4-point Likert scale (where 0 = “not at all”
and 3 = “nearly every day”). Total scores are in the range
of 0–27, with suggested cut points of 5, 10, and 15 indi-
cating mild, moderate, and severe depression, respect-
ively [40]. The PHQ-9 is a validated diagnostic measure
in primary care [65], with demonstrated efficacy and
sensitivity as an outcome measure for treatment trials
with a recommended Reliable Change Index [51].
Secondary outcomes
Self-efficacy will be measured using the Mental Health
Self-Efficacy Scale (MHSES) [66]. The MHSES comprises
six items that require respondents to rate on a 10-point
Likert scale how confident they are in performing behav-
iors related to mental health self-care (from 1 = “not at all
confident” to 10 = “totally confident”). Total scores are in
the range of 6–60 and provide a unidimensional measure
of self-efficacy; higher scores indicate greater levels of self-
efficacy. The MHSES displays high internal consistency
(Cronbach’s alpha = 0.91) and good construct validity, cor-
relating well with measures of depression, anxiety, and
functional impairment.
The seven-item Generalized Anxiety Disorder scale
(GAD-7) will be used to assess anxiety [67]. The GAD-7
assesses the presence of anxiety symptoms over the past
two weeks using a 4-point Likert scale. Scoring is similar
to the PHQ-9; each item is scored from 0 to 3 (for a
total possible score of 0–21), with cut points of 5, 10,
and 15 corresponding to mild, moderate, and severe
anxiety symptoms. The GAD-7 has excellent internal
consistency (Cronbach’s alpha = 0.92) and test–retest
reliability. Its construct, convergent, and discriminant
validity are high; it correlates well with measures of
depression and functioning (while assessing a distinct
construct), as well as with other measures of anxiety.
Quality of life will be assessed at each time point using
the Assessment of Quality of Life (AQoL-8D) [68]. This
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is a validated, reliable measure [69] that comprises eight
dimensions (independent living, senses, pain, mental health,
happiness, self-worth, coping, and relationships) that can
be used to calculate quality-adjusted life years (QALYs) via
a utility algorithm. The AQoL-8D has been shown to be
sensitive to depressive symptom severity levels [69].
Cost-effectiveness of the intervention will be measured
through assessment of health service use, effects on
productivity, and calculation of QALYs. Health service
use will be tracked using data extracted from the Austra-
lian Government Department of Health: the Medicare
Benefits Schedule (MBS) that maintains information
about visits to healthcare providers and diagnostic tests;
and the Pharmaceutical Benefits Scheme (PBS) database
of medications supplied on prescription. Participants will
provide additional consent to access their MBS and PBS
data. Other resource use not captured by these national
databases, including the use of broader health and welfare
services and effects on productivity (i.e. education and
workforce participation), will be assessed via self-report
using an adapted questionnaire developed by members of
the research team and used in numerous other Australian
mental-health intervention trials [70–72].
Process data
To complement the outcome data collected as part of
the RCT, a parallel process evaluation will be conducted
in order to understand the context in which the outcomes
were achieved. The evaluation will identify challenges of
implementation and provide important guidance for fu-
ture translation of trial findings, using the framework set
out by the Medical Research Council [73]. The process
evaluation will draw from data collected through a variety
of sources, including but not limited to recruitment log-
books, interviews and surveys of GP and practice staff,
intervention uptake and adherence data (as described
above), and interviews with randomly selected participants
(across both the two study arms and three depressive
symptom severity groups). A comprehensive protocol for
this evaluation will be published separately.
Fig. 2 Schedule of enrolment, interventions and assessments. PHQ-9 Patient Health Questionnaire – 9; GAD-7 Generalized Anxiety Disorder scale;
MHSES Mental Health Self-Efficacy Scale; AQoL-8D Assessment of Quality of Life scale; MBS Medicare Benefits Schedule; PBS Pharmaceutical Benefits Scheme
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Retention
To encourage retention at each study time point, non-
responders will receive up to five reminders in total via
phone, text, and email. These reminders will also pro-
vide the option of completing the baseline, three-month,
or 12-month survey over the phone with an RA or being
mailed a hard copy of the questionnaire to complete and
return via reply paid envelope. At three and 12 months,
participants who still do not complete the survey will be
offered the option of completing the primary outcome
measure (PHQ-9) alone. Outcome assessments may be
completed in multiple sittings, with participants pro-
vided the option of saving their responses and returning
later via a link emailed to them upon exiting the survey.
To acknowledge the time spent by participants and to
further promote retention at three and 12 months, ran-
dom draws for a $100 gift card will be conducted
monthly for each follow-up survey, with all participants
who completed the survey in the previous month eligible
to receive a gift card. The selected participant will be
contacted via phone and email. Participants will be ad-
vised of the draw in the initial email with their unique
link to the relevant survey and in subsequent reminders.
Data management
Participants will enter data directly into the Target-D
website, which will store responses coded according to
standard practice for each validated questionnaire. The
website presents each item on a separate page to minimize
the chance of items inadvertently being missed. Data in-
tegrity will be enforced through the use of forced or mul-
tiple choice items wherever possible; valid value and range
checks will also be built into the website for free text fields
where appropriate.
The coded study data will be downloaded weekly from
the Target-D website, stored securely, and backed up
regularly on a central password-protected University sys-
tem. A data manager will check all data to identify and,
where possible, resolve errors prior to analyses being
conducted. Data will be kept for 15 years after study
completion after which time they will be destroyed in
accordance with University protocol [74].
The Research Electronic Data Capture (REDCap) se-
cure software application [75] will be used to manage
contact with participants and track progress through the
study, with participant information transferred manually
into REDCap from the Target-D study website. Both
REDCap and the Target-D website are password-protected
and housed on secure University servers; only the study
team will have access to the identified data.
Statistical methods
Descriptive statistics will be used to compare participant
characteristics between the study arms, in total and
stratified according to depressive symptom severity group.
Linear mixed-effects model using restricted maximum
likelihood with random intercepts for individuals will be
used to estimate the difference in mean outcome between
study arms at three and 12 months. All regression models
will adjust for baseline outcome measure (where appropri-
ate), stratification factors (practice, depressive symptom
severity group) and time (baseline, three and 12 months),
with a two-way interaction between study arm and time
except baseline where means in the study arms will be
constrained to be equal. Baseline variables strongly associ-
ated with the outcome that are found to be imbalanced
between the study arms will also be considered for adjust-
ment in the regression analyses. Estimated intervention ef-
fects will be reported as the difference in the means of the
outcome between study arms (intervention-comparison),
with 95% confidence intervals and p values. Similar regres-
sion analyses will also be used to compare the outcomes
between intervention and comparison arms separately for
each of the three depressive symptom severity groups. In a
secondary analysis, we will investigate the intervention ef-
fect on individuals who would comply with their assigned
treatment using a complier average casual effect (CACE)
analysis [76]. A detailed analysis plan will be developed for
the secondary and sensitivity analyses. All analyses will be
performed using Stata 13.0 [77].
Missing data
Analyses will use an ITT approach, where participants will
be analyzed in the study arm to which they were allocated
[78]. In the first instance, we will implement strategies
to minimize the missing outcome data, including the
participant retention strategies outlined above. Reasons
participants are lost to follow-up will be recorded. Sen-
sitivity analysis will be used to assess the robustness of
the missing data assumption.
Cost-effectiveness and cost-utility analysis
Incremental cost-effectiveness ratios (ICERs) will be deter-
mined (cost of intervention – costs of comparison/out-
come of intervention – outcome of comparison) using the
AQoL-8D to determine QALYs. ICERs using other im-
portant study outcomes (such as cost per remitted case)
will also be determined. Variation will be determined by
bootstrap and regression analyses and results presented in
cost-effectiveness planes and acceptability curves. Sensitiv-
ity analyses will also be used to determine the impact of
important study parameters (such as unit cost price vari-
ation). Dependent on trial results, modeling may also be
used to extrapolate beyond the trial time horizon.
Monitoring
The Target-D study will be monitored by the Steering
Committee (SC) and a Data Monitoring Committee
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(DMC). The SC will comprise all named investigators
and the project manager and will be led by the Chief
Investigator. The SC will have biannual meetings to
monitor recruitment progress, troubleshoot any areas
of concern, ensure that the project is being conducted
according to protocol, and identify additional training
or support required by the research staff to facilitate
the smooth running of the trial.
The DMC will comprise at least three members and
be led by Professor Jon Emery, an experienced re-
searcher independent of the research team. Collectively,
DMC members will have clinical, research, and statistical
expertise across primary care and mental health. Mem-
bers of the DMC will be provided with a Charter outlin-
ing their scope of responsibilities (Additional file 5). The
DMC will meet biannually to monitor trial processes
and progress, and review complaints, harms, and adverse
events. Adverse events may be serious or otherwise; the
former are defined as those which “might be significant
enough to lead to important changes in the way the
[intervention] is developed” [79]. In light of the fact that
the interventions used in the study are evidence-based,
and all participants are linked in with health services,
routine data collection will assess adverse events and no
interim analyses or auditing are planned. All adverse
events will be recorded (including relation to study, se-
verity, potential for the event to have been anticipated,
and action taken) and reported to the DMC. Serious ad-
verse events will also be reported to the University ethics
committee.
Ethics and dissemination
The University of Melbourne Human Research Ethics
Committee (HREC) has approved this study protocol
(ID number 1543648). Collection of MBS and PBS
data has been approved by the Australian Government
Department of Human Services Information Services
Branch (ID: MI3794). Approval from these two ethics
committees applies to all study sites. Any substantive
modifications to this protocol that affect the conduct
or nature of the study will be submitted to the respon-
sible HREC for approval prior to implementation.
Eligible patients will receive a plain language statement
outlining the potential risks and benefits of participating
in Target-D and give informed consent to participate in
the study through the Target-D website. A copy of the
plain language statement will also be provided via email.
Consent will apply only to the current research study.
Participants will be advised at the time of study consent
that they will be asked for separate consent to collect
their MBS/PBS data. Participants will subsequently re-
ceive a plain language statement regarding MBS and
PBS data collection (Additional file 4) and a link to
provide informed consent online. Participants will be
advised that consenting to provide access to their
MBS/PBS information is optional and will not affect
their participation in Target-D. All information provided
to participants regarding the collection of this data ad-
heres to Australian Government requirements.
Confidentiality of participants will be protected by as-
signment of an identification number to each partici-
pant. Participants’ study information will not be released
outside of the study without permission, except where
maintaining confidentiality endangers the health or safety
of the participant or someone else. Only investigators in-
cluded in the original ethics applications or subsequent
amendments will have access to the identified dataset.
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interest will have no undue influence on the study find-
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Dissemination policy
Regardless of the magnitude or direction of effect, the
results of this trial will be presented at relevant research
conferences and as published articles in peer-reviewed
journals. The study will be reported following the
CONSORT and TIDier guidelines. Authorship eligibility
guidelines at the respective institutions will be followed.
The results of the trial will be communicated to partici-
pants via a trial newsletter and to the involved GP clinics
via a personal visit and community reports. The findings
from this trial have the potential to affect healthcare policy
and will be reported to relevant government bodies. There
are no plans to allow public access to the dataset or statis-
tical code.
Discussion
The burden of disease associated with depression is large
and shows no sign of decreasing, despite significant in-
vestment in an array of effective treatments. One reason
for this is suggested to be poor allocation of treatment,
with both over-treatment for mild symptoms and under-
treatment for severe symptoms common. Stepped care
models, in which people receive the least time and re-
source intervention that will be effective, are posited as a
solution to this mismatch; however, there is currently no
systematic way of identifying which “step” of treatment
an individual should be allocated to. In addition, mental
health lags behind other fields of medicine in focusing
on which step is appropriate given the person’s current
symptoms, rather than their future course of illness.
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We have therefore developed a new CPT which pre-
dicts depressive symptom severity at three months and
provides an evidence-based treatment recommendation
accordingly. In the Target-D trial, we will test whether
using this tool to match individuals to treatment is a
clinically effective and cost-efficient way of reducing de-
pressive symptom severity, relative to usual care. If the
Target-D model for depression management is efficacious
and cost-effective, implementation into practice could
reduce unnecessary treatment burden and improve al-
location of treatment resources.
Trial status
At the time of submission, patient recruitment to the
Target-D trial is ongoing. The anticipated study comple-
tion date is July 2018.
Endnotes
1myCompass users can elect to receive helpful tips,
facts, and motivational messages via SMS or email. The
program also offers SMS/email reminders to facilitate
symptom tracking and completion of homework activities;
users can opt in and out of these services as they wish and
can choose the frequency and timing of messages.
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